01 October 2005
Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia: Final report of the Polish Adult Leukemia Group (PALGCLL1).
Tadeusz Robak, Jerzy Z Błoński, Marek Kasznicki, Joanna Góra-Tybor, Anna Dmoszyńska, Maria Wojtaszko, Aleksander B Skotnicki, Wiesław Nowak, Andrzej Hellmann, Krzysztof Lewandowski, Barbara Zdziarska, Lech Konopka, Bernadetta Ceglarek, Jadwiga Dwilewicz-Trojaczek, Piotr Boguradzki, Kazimierz Kuliczkowski, Kazimierz Sułek, Krzysztof WarzochaMed Sci Monit 2005; 11(10): PI71-79 :: ID: 430316
Abstract
BACKGROUND: We previously published an early report of a randomized, multicentertrial on the efficacy and toxicity of cladribine (2-CdA) + prednisone (P) compared with chlorambucil(Chl) + P in previously untreated patients with progressive or symptomatic chronic lymphocytic leukemia.Here we present the final report of this study. MATERIAL/METHODS: Of 229 patients, 126 received 2-CdA+Pand 103 Chl+P. Patients with no response or progression after three courses or who relapsed earlier than12 months after completing one treatment were switched to the other. Patients who relapsed later wereretreated with the same schedule as before. RESULTS: Thirty-three patients were retreated with 2-CdA+Pand 19 with Chl+P. Overall response (and complete response) rates were 35% (6%) and 47% (16%), respectively.In 50 patients initially treated with Chl+P and then with 2-CdA+P, complete response (CR) was achievedin 12 (24%) and overall response (OR) in 32 (64%). In 28 patients originally treated with 2-CdA+P andthen with Chl+P, CR in 1 (3%, p=0.01) and OR in 6 (21%, p=0.003) were obtained. We found no statisticallysignificant difference in overall survival time in patients treated initially with 2-CdA+P and Chl+Paged 60 years (4.63 and 5.27 years, respectively, p=0.45), 60-70 years (3.29 and 3.14 years, p=0.79),and >70 years (1.53 and 1.93 years, p=0.11). CONCLUSIONS: 2-CdA+P is significantly more effective asa second-line treatment and re-treatment than Chl+P. However, we found a trend to longer survival inelderly patients treated with Chl+P.
Keywords: Cladribine - administration & dosage, Chlorambucil - administration & dosage, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Cyclophosphamide - administration & dosage, Doxorubicin - administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy, Prednisone - administration & dosage, Vincristine - administration & dosage
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
06 Mar 2024 : Clinical Research
Prevalence and Variation of Medical Comorbidities in Oral Surgery Patients: A Retrospective Study at Jazan ...Med Sci Monit In Press; DOI: 10.12659/MSM.943884
08 Mar 2024 : Clinical Research
Evaluation of Foot Structure in Preschool Children Based on Body MassMed Sci Monit In Press; DOI: 10.12659/MSM.943765
15 Apr 2024 : Laboratory Research
The Role of Copper-Induced M2 Macrophage Polarization in Protecting Cartilage Matrix in OsteoarthritisMed Sci Monit In Press; DOI: 10.12659/MSM.943738
07 Mar 2024 : Clinical Research
Knowledge of and Attitudes Toward Clinical Trials: A Questionnaire-Based Study of 179 Male Third- and Fourt...Med Sci Monit In Press; DOI: 10.12659/MSM.943468
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952